This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
Age 18 years or older
Individuals eligible for keratoprosthesis surgery, as determined by standard-of-care eligibility criteria
Patients with poor prognosis for corneal transplantation, severe corneal opacity and/or vascularization
Patients with vision worse than 20/200 in the eligible eye, and contralateral eye with vision less than 20/40
Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-# release assay [IGRA] test, such as Quantiferon-gold)
Untreated active hepatitis B or C infection.
Ocular or periocular malignancy and/or infection
Inability to wear contact lens